Diagnostics Pipeline

The Company has a cancer diagnostics portfolio of marketed and development-stage products for multiple cancer indications. The portfolio includes the marketed hTERT test for diagnosis of bladder cancer, with the development-stage BARD1 autoantibody tests for early detection of ovarian, breast and lung cancers, and the research-stage EXO-NET exosome-based liquid biopsy pipeline. The combined diagnostics portfolio includes: